Introducing home treatment with bortezomib (Velcade®)
The COVID-19 pandemic brought challenges to the delivery of care for haematology patients on an unprecedented level. Teams faced an urgent need to restructure ‘routine’ services to allow myeloma treatments to carry on as much as possible, while also reducing the risk to this particularly vulnerable group of patients.